Analyst consensus rating
AstraZeneca Analyst Rating: Buy
Direct answer
AstraZeneca's consensus rating is Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $206.66.
Forecast evidence checked October 27, 2026.
Get free AstraZeneca email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $170.08
- Average price target
- $206.66
- High price target
- $240.00
- Low price target
- $158.00
- Low target gap
- -7.1%
- Target upside
- +21.5%
- High target gap
- +41.1%
- Target range width
- 48.2%
- Consensus rating
- Buy
- Analysts
- 12
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AstraZeneca?
AstraZeneca has a verified Buy consensus. The same dataset has an average price target of $206.66.
How far are AstraZeneca's low and high targets from the recorded price?
The low target implies -7.1%, while the high target implies +41.1%.
How many analysts are included in AstraZeneca's consensus?
The verified consensus includes 12 analysts.
How is AstraZeneca's target upside or downside calculated?
The average target of $206.66 is divided by the recorded price of $170.08, then one is subtracted to produce +21.5%. This does not guarantee a future return.
When was AstraZeneca's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.